View Author
patient cancer erlotinib growth study epidermal toxicity egfri follicle flammatory factor receptor sebaceou gland treatment biopsy skin toxicity sebaceous glands differentiation trail filtrate inhibitor effect structure 150 mg journal model keratinocyte development rash biopsies flammation response grade escalation neutrophil result nsclc oncol cancer 4 6 egfr inhibition hair follicles egfr inhibitors damage trail-positive agent cutaneou inhibition non-small-cell lung cancer european dermi dc morphology dendritic t-cell filtrate neutrophil trial acne vulgaris activity dermatol level mouse flammatory dendritic cells pathology apoptosi filtration vulgari epithelium epithelial month mouse models trail-positive cells macrophage identi phase carcinoma tissue epidermis european journal terminal differentiation dose escalation anticancer activity
3 Most Recent Publications
|
Erlotinib dosing-to-rash: A phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer
(Article)
Mita, A. Papadopoulos, K. Hamilton, M. Iwata, K.K. Wacker, B. Witte, K. de Rowinsky, E.K. Jonge, M.J.A. de Schwartz, G. Verweij, J. Ricart, A. Chu, Q.S.C. Tolcher, A.W. Wood, L. McCarthy, S.W. |
2011-09-27
|
|
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
(Article)
Guttman-Yassky, E. Mita, A. Jonge, M.J.A. de Matthews, L. McCarthy, S. Iwata, K.K. Verweij, J. Rowinsky, E.K. Krueger, J.G. |
2010-07-01
|
|
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
(Article)
Guttman-Yassky, E. Mita, A. Jonge, M.J.A. de Matthews, L. McCarthy, S.W. Iwata, K.K. Verweij, J. Rowinsky, E.K. Krueger, J.G. |
2010-01-01
|
